NutriBand Inc.
Close on Oct 19, 2026
- Market cap
- $72.94M
- P/E (TTM)
- –
- Dividend yield
- –
About NutriBand
Orthopedic, Prosthetic & Surgical Appliances & Supplies, SIC 3842
Nutriband Inc. is a pharmaceutical company that develops transdermal drug delivery systems, focusing on abuse-deterrent technologies. Its proprietary AVERSA platform incorporates aversive agents into patches to prevent the misuse and accidental exposure of opioids and stimulants. The development pipeline includes transdermal fentanyl, buprenorphine, and methylphenidate. Nutriband operates through two segments: Pocono Pharmaceuticals and 4P Therapeutics. Pocono provides contract manufacturing services for health, wellness, and over-the-counter pharmaceutical clients, while 4P Therapeutics conducts contract research and development for pharmaceutical and medical device customers.
The company is headquartered in Orlando, Florida. Its subsidiary Pocono Pharmaceuticals operates a manufacturing facility in Cherryville, North Carolina. Nutriband primarily conducts business and generates most of its revenue in the United States, alongside operations serving non-U.S. markets.
Summary of the business section of NutriBand's latest annual report, written by StockData.
Company profile
Company
- Legal name
- NutriBand Inc.
- Founded
- 2012
- Headquarters
- Orlando, FL
- Address
- 121 S. Orange Ave., Suite 1500 32801
- Phone
- (407) 377-6695
- Website
- nutriband.com
- Employees
- 500, Jan 31, 2026
- Industry
- Orthopedic, Prosthetic & Surgical Appliances & Supplies
- Incorporated in
- Nevada
- Fiscal year ends
- January 31
- Auditor
- Sadler, Gibb & Associates, LLC, Draper, UT
Stock & identifiers
- Ticker
- NTRB
- Exchange
- Nasdaq
- Shares outstanding
- 12M, Sep 4, 2026
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-4 reverse, Sep 13, 2019
- SEC CIK
- 1676047
- CUSIP
- 67092M208
- ISIN
- US67092M2089
- LEI
- 549300OZV3WLQQWOD724
- EIN
- 81-1118176
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Gareth Sheridan | Chief Executive Officer, Director | 1,761,667 |
| Serguei Melnik | President and Secretary, Director | 1,127,999 |
| Gerald Goodman | Chief Financial Officer | 66,085 |
Employees
Headcount reported in annual reports
“While we believe we meet the criteria because we have fewer than 500 employees and no prior approved products, there is no guarantee the”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 30, 2026 | Delisting | Notice of delisting from exchange (Form 25) |
| May 1, 2024 | Late filing | Notification of late filing |
| Sep 29, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
| Oct 31, 2018 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Sep 17, 2018 | Late filing | Notification of late filing |
| Jun 14, 2018 | Late filing | Notification of late filing |
| Sep 14, 2017 | Late filing | Notification of late filing |
| Jun 14, 2017 | Late filing | Notification of late filing |
| May 4, 2017 | Late filing | Notification of late filing |